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Signalling by receptor tyrosine kinases (RTKs) coordinates basic cellular processes during development and in adulthood.
WhereasaberrantRTKsignallingcanleadtocancer,reactivationofRTKsisoftenfoundfollowingstressorcelldamage.Thishas
led to the common belief that RTKs can counteract degenerative processes and so strategies to exploit them for therapy have
been extensively explored. An understanding of how RTK stimuli act at cellular levels is needed, however, to evaluate their
mechanism of therapeutic action. In this study, we genetically explored the biological and functional signiﬁcance of enhanced
signalling by the Met RTK in neurons, in the context of a neurodegenerative disease. Conditional met-transgenic mice, namely
Rosa26
LacZ stop Met, have been engineered to trigger increased Met signalling in a temporal and tissue-speciﬁc regulated
manner. Enhancing Met levels in neurons does not affect either motor neuron (MN) development or maintenance. In contrast,
increased neuronal Met in amyotrophic lateral sclerosis (ALS) mice prolongs life span, retards MN loss, and ameliorates motor
performance, by selectively delaying disease onset. Thus, our studies highlight the properties of RTKs to counteract toxic
signals in a disease characterized by dysfunction of multiple cell types by acting in MNs. Moreover, they emphasize the
relevance of genetically assessing the effectiveness of agents targeting neurons during ALS evolution.
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Signalling by receptor tyrosine kinases (RTKs) is involved in
cell communication events regulating tissue morphogenesis
during development and tissue homeostasis during adult-
hood.
1 In vivo, RTK signalling levels vary according to a
number of parameters, such as RTK expression levels, ligand
availability, action of positive/negative signalling regulators,
and components of the signalling cascade. The levels of RTK
signalling determine qualitatively different biological out-
comes.
2 Given the multiple roles of RTKs in coordinating
basic biological processes, modulating their activation levels
is a means of achieving different cellular responses in normal
processes and in pathological conditions. Notably, RTK
activation is tightly regulated in healthy adult tissues as
aberrant signalling in susceptible cells can cause pathologies,
such as cancer.
1,3 Conversely, studies on degenerative
diseases have shown that following stress or cell damage
there is nearly always a reactivation of RTK signalling,
coinciding with periods of active ﬁght for survival/repair.
4,5
For example, genetic analysis of RTK functions in neurode-
generative processes have demonstrated their requirement
forrepairofdamagedtissues.
4Incontrast,studiesoncultured
cells and on animal models have shown that symptoms linked
to degenerative diseases can be ameliorated when activation
of appropriate RTKs is achieved through exogenous ligand
administration.
4,6 However, it is still not clear to which extent
levels of remobilized endogenous RTKs are limiting for
effective neuronal repair in disease CNS.
Over the last years, a regional and temporal map of RTK-
dependency has emerged, suggesting that an appropriate
enhancement of RTK signalling might be beneﬁcial to
efﬁciently counteract disease onset and progression. This
issue is particularly relevant for neurodegenerative diseases,
such as amyotrophic lateral sclerosis (ALS), an adult onset
motorneuron(MN)diseasecausedbypathologicalprocesses
occurring in both neuronal and non-neuronal cells.
7 ALS
involves progressive degeneration of upper and lower MNs,
culminating in muscle wasting, and death mostly due to
respiratory failure. Although the aetiology of most cases
remains unknown, 10–20% of familial ALS is caused by
mutations in the superoxide dismutase1 (SOD1) gene.
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www.nature.com/cddisConsistently, transgenic mice expressing the mutant forms
of human SOD1 recapitulate a number of ALS symptoms
and have been instrumental in evaluating the molecular
and cellular events underlying ALS pathology.
7 Moreover,
genetic and cell biological studies based on the differential
expression of mutant SOD1 in distinct cell types have
demonstrated that although death of MNs causes ALS
symptoms, the disease also renders other cells, such as
astrocytes and microglia, dysfunctional. Thus, MN loss, in
addition to a cell-autonomous origin, is also triggered by non-
cell-autonomous defects involving toxicity of other unhealthy
cells.
8,9 Notably, these different cell types play distinct roles in
ALS pathogenesis. Damage within MNs is primarily asso-
ciated with disease onset and its early progression phase,
whereas damage within microglia and astrocytes accelerates
MN degeneration and ALS progression.
8–12 The recognition
that multiple cell types determine ALS evolution has boosted
the need to understand the relative contribution of providing
beneﬁcial signals to different cell types involved in the
disease.
Among several strategies to alleviate ALS symptoms, a
major hope has been placed on the ability of trophic factors,
acting on MN in culture or during development,
4,7 to activate
endogenous RTKs. Initial results were disappointing as
infusion of speciﬁc trophic factors had little or no beneﬁcial
effects. The weakness of these approaches appeared to be
inadequate delivery of these factors to the right cells. This
possibility was further supported by genetic studies assessing
growth factor efﬁcacy depending on the delivery site.
13,14
Therefore, understanding the relative contribution of enhan-
cing RTK signalling in distinct cell types is needed to further
clarify the ALS biology and to evaluate how beneﬁcial signals
should be delivered for therapy.
In this study, we assessed the biological and functional
signiﬁcance of enhanced signalling, above endogenous
levels, downstream of the Met RTK speciﬁcally in neurons
during neuro-degenerative diseases, such as ALS. A number
of features makes the Met receptor of special interest to
address RTK signalling levels during neuro-degenera-
tion.
15,16 During development, activation of the Met receptor
by its ligand HGF regulates MN fate at multiple levels,
including identity acquisition, axonal growth, and survival.
2,17–20
During injury, HGF is able to enhance regeneration of the
lesioned spinal cord and of crushed peripheral nerves.
21,22
Intracerebral delivery or transgenic-mediated neuronal
expression of HGF in mutant SOD1 animal models acts
simultaneously on different dysfunctional cell types.
23,24
However, the contribution of enhancing Met signalling
uniquely in neurons and its relative impact on ALS
onsetand progressionremains to beestablished. Toenhance
Met signalling above a threshold level in a temporal
and tissue-speciﬁc manner, we generated conditional met
transgenic mice using the cre-loxP system. Here, we show
that transgene-mediated neuronal expression of the Met RTK
in SOD1
G93A mice selectively delays disease onset,
without slowing down its progression. Our ﬁndings show that
boosting RTK signalling in a cell-type-restricted manner can
have a distinct beneﬁcial impact in counteracting the
processes underlying the evolution of neurodegenerative
diseases.
Results
Generation of conditional Rosa26
LacZ stop Met
transgenic mice. To enhance Met signalling levels in a
temporally and spatially regulated manner, we generated
mice carrying a conditional mouse–human chimeric met
transgene (met
tg). In particular, we engineered a mouse
strain in which a cytomegalovirus (CMV)-enhancer/b-actin-
promoter controls the expression of a ﬂoxed-b-geo-reporter
gene followed by a met
tg. Such a strategy was chosen to
keep the met
tg silent, unless the stop cassette is excised by
cre-mediated recombination. To avoid integration site effects
and favour loxP-site accessibility, the construct was inserted
into the Rosa26 locus (Rosa26
LacZ stop Met, referred to
R26
LacZ stop Met; Figures 1a–c).
To speciﬁcally gain expression in neural cells, we crossed
the R26
LacZ stop Met mice with the nestin-cre transgenics
25
(nestin-cre;Rosa26
LacZ stop Met, referred to as Nes-R26
Met),
leading to the excision of the lacZ-ﬂoxed cassette and
consequently expression of the Met chimeric protein (Met
tg)
in neural tissues (Figures 1c and d). Western blot analysis of
E15.5 embryos and P7 mice revealed the presence of Met
tg in
dissected brains and spinal cords only after recombination
(Figure 1d). To estimate Met
tg levels versus endogenous Met,
we performed western blot analysis of brain and spinal cord
protein extracts at different developmental stages using
antibodiesrecognizingthekinasedomainofbothendogenous
and Met
tg. Quantiﬁcation analyses indicated that Met
tg levels
were at least 5/7-fold increased in brains and spinal cords of
heterozygous Nes-R26
Met, when compared with endogenous
mouse Met (Figures 1e and f). Consistently, Met
tg levels were
twofold higher in homozygous mice compared to hetero-
zygous littermates (Figures 1d–f).
We next characterized the R26
LacZ stop Met mice before
and after recombination by following the expression of the
lacZ-stop cassette and met
tg transcript in adult brains and
spinal cords. We found a decrease in b-galactosidase activity
and lacZ transcripts in Nes-R26
Met compared with R26
LacZ -
stop Met transgenics, indicating that recombination in several
brain regions occurred as expected (Figures 2a–d, Supple-
mentary Figures 1 and 2). Conversely, met
tg was expressed
in brains only after recombination in a pattern complementary
to lacZ distribution (Figures 2e and f). High levels were found
in the hippocampus, cerebellum, cerebral cortex, and cervical
spinal cord (Figures 2g–i). Expression studies performed
on adult lumbar spinal cord sections revealed also a
complementary distribution pattern. In particular, lacZ or
met
tg were found in cells with large nuclei resembling MNs
of R26
LacZ stop Met and Nes-R26
Met, respectively (Figure 3).
Quantiﬁcation analysis revealed that cre-mediated excision
occurred in approximately 56% of these cells (56.3±1.1;
Po0.0001; Figure 3g).
Molecular and cellular characterization of Nes-R26
Met
mice. Although the Rosa26 locus drives gene expression
ubiquitously,
26 we observed that the lacZ distribution in
brains and spinal cords of adult R26
LacZ stop Met mice
appeared restricted to distinct cell types (Figures 2a–d
and 3a–f, Supplementary Figures 1 and 2). Colocalization
studies revealed b-galactosidase activity predominantly in
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Cell Death and DiseaseNeuN-positive neurons, but not in glial ﬁbrillary acidic protein
(GFAP)-positive astrocytes (Figures 4a–h). The restricted
neuronal lacZ expression was also observed in cultured cells
(Figures 4i–n). Thus, the genetic setting we adopted (CMV-
enhancer/b-actin-promoter in Rosa26) results in an animal
model with a restricted expression of the transgene,
indicating that met
tg should be predominantly conﬁned
to neurons after nestin-cre-mediated recombination. Consis-
tently, met
tg transcripts colocalized with Smi32-positive
neurons, but not with GFAP-positive astrocytes (Supple-
mentary Figure 3). The restricted expression of met
tg in
neurons was also observed in Nes-R26
Met adult spinal cords,
Figure 1 Temporal and tissue-speciﬁc Met transgene activation using Cre-mediated recombination. (a) The R26
LacZ stop Met construct targeted in the Rosa26 locus is
shown. The targeting construct consists of the CMV-enhancer and the chicken b-actin promoter (CMV/b-actin) driving the b-geo reporter and a Met chimeric cDNA. The
reporter gene is followed by three copies of the SV40 polyadenylation signal (3xpA) and ﬂanked by loxP sites. The Met chimeric cDNA consists of a 50 portion encoding the
mouseextracellulardomainfusedtoa30 regioncodingfortheintracellularhumanportion.PositionsoftheprobesusedforSouthernanalysis(aandb)aswellasprimersused
forPCR(1,2,3)areindicated.(b)Southernblotsofneo-resistantESclonesanalyzedwithprobea(EcoRIdigestion;top)andprobeb(EcoRVdigestion;bottom).The15.5Kb
band corresponds to the wild-type allele whereas the 5.5Kb band depicts the recombinant allele in clones 1 and 2. (c) PCR of mouse-tail genomic DNAs showing the mutant
allele before and after Cre recombination (top). The presence of an amplicon in the Nes-R26
Met mice with the 1þ2 primers is detected because genotypes are performed
using DNA extracted from tails, which include tissues with and without recombination. PCR showing the genotypes of heterozygous and homozygous Nes-R26
Met mice
(bottom). (d) Western blots showing the expression of the Met chimeric protein (using anti-human Met antibodies) in brain and spinal cord extracts from embryos (E15.5) and
newborn mice (P7) with the indicated genotypes. (e) Quantiﬁcation analysis of Met chimeric protein levels versus endogenous Met. Western blot analysis of protein extracts
from dissected brains and spinal cords at different developmental stages using antibodies recognizing the Met kinase domain (Met
KD). (f) Quantiﬁcation analyses revealed
that levels of Met chimeric proteins were at least ﬁve- and sevenfolds increased in brains and spinal cords of heterozygous Nes-R26
Met, respectively, when compared with
the endogenous mouse Met. Met chimeric levels were double in homozygous mice. Numbers on columns indicate fold of increase in Met protein levels over the endogenous
Met. In the graph, Nes-R26
Met and Nes-R26
Met/Met genotypes are indicated as M/þ and M/M, respectively. Values are expressed as means±S.E.M. Tub, tubulin; hMet,
human-Met
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Cell Death and Diseasewhere it was found in dorsal horn neurons, intermediate
lateral neurons, and MNs, but not in GFAP-positive astro-
cytes (Figure 5). Thus, met
tg is predominantly restricted to
neurons in Nes-R26
Met mice.
We next examined whether Met
tg protein was active by
following its phosphorylation state using anti-phospho-Met
antibodies. High levels of phosphorylated Met
tg were found in
the pons, medulla, lateral ventricles, rostral-migratory stream,
olfactory bulbs, cerebral and lumbar spinal cords (Figure 6
and data not shown). These results show that Met
tg is
predominantlyfunctionalinspatiallyrestricteddomains,which
possibly correlate to a map of cellular competence for Met
tg
activation inﬂuenced by a combination of parameters, such
as environmental contexts (e.g., endogenous HGF levels)
or permissive intracellular mechanisms (e.g., signalling
modulators). Altogether these data show that Nes-R26
Met
mice can be a useful animal model to investigate the
functional consequences of enhancing Met levels in distinct
cell types, using available tissue-speciﬁc cre-lines.
Phenotypical characterization of Nes-R26
Met mice. As
previously discussed, Met regulates speciﬁcation, axonal
growth, and survival of MN subtypes during development.
17–20
We therefore evaluated whether enhanced Met levels
inﬂuence MN numbers in Nes-R26
Met mice. By staining
spinal cord sections either with cresyl violet or with vesicular-
acetylcholie-transporter (VAChT) antibodies, similar MN
numbers were found at thoracic (data not shown) or lumbar
spinal cord levels in Nes-R26
Met and control animals
(P40.05; Figures 7a–d and g). As expected by the
Figure 2 Molecular characterization of Nes-R26
Met and R26
LacZ stop Met mice in adult brains. (a–d) Expression of the lacZ reporter gene was followed by measuring
b-galactosidase (X-Gal) activity (a and b) or its transcript levels (c and d) on sagittal sections. Decrease in X-Gal and lacZ transcripts were found after nestin-cre-mediated
recombination. (e and f) Expression of the met chimeric transgene in sagittal section of adult Nes-R26
Met and R26
LacZ stop Met brains. (g–i) High levels of transgenic met
transcripts were detected in the hippocampus (g), cerebellum (h), cervical spinal cord (i). Panels (g–i) show enlarged views of brain areas delineated by the rectangles in (e).
cb, cerebellum; cc, cerebral cortex; h, hippocampus; sc, spinal cord
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Cell Death and Diseasecolocalization studies, no differences in GFAP-ﬂuorescence
intensity were observed (P40.05; Figures 7e, f and h).
As body weight is a generic indicator of animal physiology
inﬂuenced by body metabolism, activity, and feeding beha-
viour, the weight of Nes-R26
Met mice was followed over-time
and no signiﬁcant differences were found versus controls
(P40.05; Figure 7j). We next performed the rotarod test to
evaluate the overall motor function and no signiﬁcant
differences were found in Nes-R26
Met versus controls
(P40.05; Figure 7i). Altogether, these studies show that
enhancing Met levels in neurons does not cause gross
physiological abnormalities.
Neuronal-enhanced Met levels counteract ALS
symptoms in SOD transgenic mice. We next
investigated the functional relevance of genetically
enhancing Met signalling levels in the context of a
neurodegenerative disorder, such as the ALS. The
Nes-R26
Met mice were therefore crossed with a strain
carrying high copy numbers of the SOD1
G93A transgene to
generate an ALS animal model with increased Met levels in
neurons. Five groups of mice were generated: (a) wild-type;
(b) Rosa26
LacZ stop Met, (c) Nes-R26
Met, (d) SOD1
G93A
(referred to as SOD), and (e) Nes-R26
Met;SOD1
G93A
(referred to as Nes-R26
Met-SOD). As no signiﬁcant
changes were observed between wild-type,
Rosa26
LacZ stop Met, and Nes-R26
Met for all parameters
examined, results of control animals included these three
groups.
By evaluating the life span of SOD and Nes-R26
Met-SOD
mice, we found that neuronal-enhanced Met levels prolonged
the survival by 13 days (mean age, SOD: 136±2 days;
Nes-R26
Met-SOD: 149±3 days; P¼0.0021; Figure 8a). As
reduction of body weight is an objective measure of ALS
disease, we examined its evolution in SOD and Nes-R26
Met-
SOD mice, and found that neuronal-enhanced Met levels
delayed body weight loss. In particular, loss of 10% body
weight was retarded for 13 days (SOD: 123±3 days; Nes-
R26
Met-SOD: 136±5 days; P¼0.0094; Figure 8b), whereas
no signiﬁcant differences were observed during disease
progression (SOD: 12.9±2.5 days; Nes-R26
Met-SOD:
13±2.4 days; P40.05; Figure 8c). Together, these results
indicate that enhanced Met levels in neurons counteract ALS
symptoms in SOD transgenic mice.
Improved motor performance and delayed onset of
paralysis in SOD mice with neuronal-enhanced Met
levels. The neuro-degeneration defects causing ALS
disease lead to progressive muscle weakness, atrophy,
and paralysis. Screwed hindlimbs and locomotor defects are
among the ﬁrst symptoms affecting transgenic ALS mice. We
Figure 3 Molecular analysis of Nes-R26
Met and R26
LacZ stop Met mice in adult
lumbar spinal cords on transversal sections. (a and b) In situ hybridization using lacZ
riboprobes. (c and d) Enlarged view of the ventral regions, showing lacZ expression in
distinct cell types characterized by large cell nuclei resembling MNs in R26
LacZ stop Met
and a decrease in its levels after nestin-cre-mediated recombination in Nes-R26
Met.
(e and f) Section showing the overlap of X-Gal activity and DAPI staining in lumbar
spinal cords. X-Gal-negative cells with large nuclei were predominantly found in
Nes-R26
Met,b u tn o ti nR26
LacZ stop Met transgenics. Arrows and arrowheads points to
X-Gal-negative and X-Gal-positive cells with large nuclei, respectively. (g) Quantiﬁcation
analysis of X-Gal-positive (blue) and X-Gal-negative cells with large nuclei (resembling
MNs; white) in Nes-R26
Met mice, showing that nestin-cre-mediated lacZ excision
occurredinapproximately56%ofthesecells.Valuesareexpressedasmeans±S.E.M.
(h–k)E x p r e s s i o no ft h emet chimeric transgene in lumbar spinal cords. Panels (jand k)
show an enlarged view of ventral spinal cords and met transgenic expression in cells
resembling MNs
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Cell Death and Diseasemonitored the appearance and progression of motor defects
in SOD versus Nes-R26
Met-SOD compared with controls by
employing swimming tank and footprint assays.
27 Onset of
swimming defects was delayed by 14 days, as estimated by
the increased time that mice needed to execute this motor
task (SOD: 113±3 days; Nes-R26
Met-SOD: 127±3 days;
P¼0.0015; Figure 8d), whereas disease progression was
unchanged (SOD:3 0 ±3.9 days; Nes-R26
Met-SOD:2 2 ±2.7
days; P40.05; Figure 8e). Therefore, neuronal-enhanced
Met improved motor strength and swimming performance of
SOD mice by acting speciﬁcally on disease onset.
The motor capability of Nes-R26
Met-SOD versus SOD mice
was further evaluated by performing footprint studies (Sup-
plementary Figure 4). The forepaw/hindpaw overlap analysis
revealed a delay of 19 days in the locomotor gait dysfunction
(SOD: 108±3 days; Nes-R26
Met-SOD: 127±3 days;
Figure 5 Subcellular localization of chimeric met transcripts in lumbar spinal
cords of adult Nes-R26
Met mice. (a–c) Colocalization studies of exogenous met
transcript with NeuN protein showing met expression in neuronal cell types.
(d–f)ColocalizationstudiesofexogenousmettranscriptwithGFAPproteinshowing
that transgenic met is not predominantly expressed in astrocytes. Panels (b and e),
panels (c and f) correspond to an enlarged view of spinal cord areas indicated by
red and black rectangles in (a and b), respectively. Arrowheads in (c) point to MNs
co-expressing chimeric met transcript and NeuN protein. Arrows and arrowheads in
(f) indicate GFAP-positive astrocytes and MN expressing chimeric met transcripts,
respectively
Figure 4 Subcellular localization of the lacZ reporter gene in Nes-R26
Met and
R26
LacZ stop Met mice. (a and b) Colocalization studies of X-Gal activity with NeuN
protein showing the reporter activity in neuronal cell types. (c and d) Enlarged view
of the hippocampus area. (e–h) Colocalization studies of X-Gal activity with GFAP
protein showing that the lacZ reporter gene is not predominantly expressed in
astrocytes. Panels (g and h) correspond to an enlarged view of the hippocampus.
(i–k) Mixed cell cultures derived from E12.5 R26
LacZ stop Met spinal cords were
immunostained for neuroﬁlament-160 (red) and b-galactosidase (green) proteins.
(i–n) Astrocyte cultures from P2 R26
LacZ stop Met spinal cords immunostained for
GFAP (red) and b-galactosidase (green). DAPI was used to counterstain nuclei
(blue), scale bar: 20mm
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Cell Death and DiseaseP¼0.0009; Figure 8f), accompanied by a delay of 9 days in
the appearance of step-length defects (SOD: 106±2 days;
Nes-R26
Met-SOD: 115±2 days; P¼0.0136; Figure 8h). The
motor performance decline rate was not appreciably different
betweenSODandNes-R26
Met-SODmice,showingthatwhen
the disease has started, it progresses at the same rate
(overlap, SOD:3 0 ±3.9 days; Nes-R26
Met-SOD:2 2 ±22.7
days; P40.05; step-length, SOD:3 2 ±3.1 days; Nes-R26
Met-
SOD:3 4 ±1.7 days; P40.05; Figures 8g and i).
Neuronal-enhanced Met levels attenuate MN loss in
spinal cords of SOD mice. As motor performances were
transiently improved in Nes-R26
Met-SOD mice by delaying
disease onset, we evaluated the neuroprotective effects of
increased Met levels by quantifying lumbar spinal cord MNs.
For these studies, we selected three animals among the
Nes-R26
Met-SOD, SOD, and controls at the symptomatic
disease phase (120 days). This stage was chosen because
all behavioural studies showed signiﬁcant differences
between groups. Lumbar spinal cord sections were stained
with VAChT antibodies and MN numbers were determined
(Figures 9a–c and m). As expected, we observed a
signiﬁcant 60% MN loss in SOD mice compared with
controls (P¼0.0065). By contrast, neuronal-enhanced Met
in Nes-R26
Met-SOD mice led to an improvement of MN
maintenance as the surviving MN numbers increased by
32% compared with SOD (P¼0.0002; Figure 9m).
We next assessed to what extent enhancing Met function in
neurons inﬂuenced astrogliosis and microglia activation,
which appear at disease onset and become more prominent
during progression.
9 In contrast to controls, activated
GFAP-positive astrocytes (changes in ﬂuorescence intensity)
were detected in lumbar spinal cords, although reduced
in Nes-R26
Met-SOD compared with SOD (SOD: 15.5±
1.9 10
8; Nes-R26
Met-SOD: 9.9±1.4 10
8; P¼0.0164;
Figures 9d–f and n). Similarly, the number of microglial cells
was reduced in Nes-R26
Met-SOD mice compared with SOD
(SOD: 281.7±14.6; Nes-R26
Met-SOD: 222.1±15.5;
P¼0.0016; Figures 9g–i and o). Analysis of muscle innerva-
tion revealed that the increased MN numbers in Nes-R26
Met-
SOD was accompanied by an enhanced integrity of neuro-
muscular junctions (NMJs; SOD:1 6 ±1.8%; Nes-R26
Met-
SOD: 41.7±11.4%; P¼0.041; controls: 84.4±7.9%;
Figure 9p). Thus, increased neuronal Met levels elicit a
combinationofprotectiveeffectsindifferentcelltypes:(1)cell-
autonomous protective effects on spinal cord MNs and for
NMJ maintenance; (2) non-cell-autonomous delay of astro-
cyte activation and increased microglia cell numbers.
Discussion
Most of neurodegenerative diseases result from a combina-
torial action of pathological signals produced by neurons
themselves and by neighbouring cells acting in a non-cell-
autonomous manner.
7 A number of molecules including
trophic factors and their receptors can elicit beneﬁcial effects
on disease-related cells when applied in vitro and/or when
deliveredindiseaseanimalmodels.Understandinghowthese
Figure 6 Tissue-distribution of activated chimeric Met in adult brains and spinal cords. (a and b) Sagittal sections of adult brains showing phospho-Met staining in
Nes-R26
Met, but not in R26
LacZ stop Met mice. (c–h) Enlarged view of phospho-Met distribution in the lateral ventricle (c), pons (d), cervical spinal cord (e), corresponding to
regions indicated by squares in panel (a). Distribution of phospho-Met in the hippocampus (f), olfactory bulb (g), and lumbar spinal cord (h). Arrowheads in (e and h) point to
phospho-Met-positive cells with large nuclei resembling MNs. cb, cerebellum; cc, cerebral cortex; lv, lateral ventricle; ob, olfactory bulb; p, pons; sc, spinal cord
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Cell Death and Diseasemolecules act on dysfunctional cells remains a key topic to
clarify disease mechanisms and to evaluate their use for
therapies. We show here that enhanced signalling by Met has
an impact on a speciﬁc stage of ALS pathology when it is
selectively upregulated in neurons. Indeed, transgene-
mediated neuronal expression of Met elicits a beneﬁcial
effect in SOD1
G93A by delaying disease onset, but not
progression.
Our results are based on a genetic approach involving the
generation of conditional met
tg mice, in which Met signalling
levels is modulated in a temporally and spatially regulated
manner. Such an approach offers the possibility of exploring
how enhanced Met signalling above endogenous levels
inﬂuences cell fate in developmental events, in adult
physiology, and in pathological conditions. Loss of Met
function during development interferes with identity acquisi-
tion, axonal growth, and survival of MN subsets.
2,17–20 We
show here that neuronal-enhanced Met signalling levels do
not affect either MN development or function in adulthood,
whereas it inﬂuences MN maintenance in ALS pathological
conditions. Thus, it is likely that excessive Met functions are
restrained by mechanisms such as tissue homeostasis or by
limiting amounts of ligand. Importantly, the dispensable
function of Met in several adult tissues is in contrast to its
requirement in counteracting degenerative processes follow-
ing injuries, such as axotomy,
21,22 hepatectomy,
28 and skin-
wound.
29 These regenerative studies together with our
ﬁndings indicate that in a pathological context, cell types like
neurons become sensitive to the beneﬁcial effects provided
by Met. The generation of compound transgenics by crossing
the R26
LacZ stop Met mice with available cre-lines will offer a
unique genetic setting for determining tissue-speciﬁc sensi-
tiveness to enhanced Met signalling either during develop-
ment, in adulthood, or in pathologies.
The pleiotropic functions elicited by the HGF/Met system in
neurons have boosted the interest in exploring its potential for
Figure 7 Molecular and functional characterization of Nes-R26
Met mice versus
controls. (a–f) Transversal sections through lumbar spinal cords showing similar
numbers of VAChT-positive (a–d) and GFAP-positive (e and f) cells. (g and h)
Quantiﬁcation studies showed no signiﬁcant difference in numbers of VAChT-
immunopositive cells (g; P40.05) and GFAP-ﬂuorescence intensity (h; P40.05)
among the two groups of mice (n¼3). (i) Rotarod behavioural analysis in
Nes-R26
Met and control littermate mice showing that enhanced neuronal Met levels
did not signiﬁcantly inﬂuence locomotor performance (P40.05; n¼10). (j) Body
weight analysis in Nes-Met
tg and control mice showed no signiﬁcant differences
overtime. Body weight is expressed as weight evolution compared with that of mice
at age 77 days. Values are expressed as means±S.E.M.
Figure 8 Neuronal-enhanced Met signalling levels in ALS mice improves survival and locomotor performance by delaying disease onset. (a) Survival analysis of
Nes-R26
Met-SOD (red) and SOD (green) mice (n¼40) showing a delay of 13 days of average life span. (b) The loss of 10% body weight was 13 day delayed in Nes-R26
Met-
SOD (n¼11) compared with SOD (n¼17) mice. (c) Body weight loss was not signiﬁcantly different in Nes-R26
Met-SOD compared with SOD mice once the disease started
(P40.05). (d and e) Motor performance analysis using a 1 meter swimming tank device. Panel (d) shows a delay of 14 days in motor defect onset of Nes-R26
Met-SOD mice
(n¼11) compared with SOD transgenics (n¼17). Panel (e) shows the analysis of the duration of locomotor defects with not signiﬁcant differences between groups
(P40.05). (f–i) Comparisonof motorperformanceusingthefootprinttest.Analysisof theforepaw/hindpaw overlaprevealed a 19 day improvement in Nes-R26
Met-SODmice
(n¼11)comparedwithSODtransgenics(n¼17;f).Nosigniﬁcantdifferenceswerefoundduringdiseaseprogression(g;P40.05).Steplengthdefectsalsoappearedwitha
delay of 9 days in Nes-R26
Met-SOD compared with SOD mice (h). Again, no changes were found during disease progression (i; P40.05). a, b, d, f and h are Kaplan–Meier
curves. Values are expressed as means±S.E.M.
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Cell Death and DiseaseFigure9 EffectsofenhancedMetsignallinginMNmaintenanceandastrogliosisatALSsymptomaticphase(120days).(a–c)VAChT-stainedsectionsthroughtheventralhornof
the lumbar spinal cord showed an increase in MN maintenance in Nes-R26
Met-SOD compared with SOD transgenics. (d–f) GFAP-stained sections through the ventral horn of the
lumbarspinalcordsshowingastrogliosisinNes-R26
Met-SODandSODmice.(g–i)Iba-1-stainedsectionsthroughtheventralhornofthelumbarspinalcordsshowinganincreaseinthe
number of microglial cells in Nes-R26
Met-SOD and SOD mice. (j–l) Immunoﬂuorescence staining of gastrocnemius muscle with a-bungarotoxin-tetramethylrhodamine (red), anti-
neuroﬁlament(green).Scalebar50mm. (m) QuantiﬁcationofMNnumbers (VAChT-positive) amongthethreegroups ofmice,showinga32%increasein Nes-R26
Met-SODcompared
with SOD mice (Nes-R26
Met-SOD versus SOD: P¼0.0002; SOD versus control: Po0.0001; Nes-R26
Met-SOD versus control: P¼0.006; n¼3). (n) Quantiﬁcation of ﬂuorescence
intensity of GFAP-immunopositive cells. Signiﬁcant differences were observed between the three groups (Nes-R26
Met-SOD versus SOD: P¼0.0164; SOD versus control:
P¼0.0002; Nes-R26
Met-SOD versus control: P¼0.0084; n¼3). (o) Quantiﬁcation of Iba-1-positive cells. Signiﬁcant differences in microglia numbers were observed between the
three groups (Nes-R26
Met-SOD versus SOD: P¼0.0016; SOD versus control and Nes-R26
Met-SOD versus control: Po0.0001; n¼3). (p) The percentage of a-Bungarotoxin-
stained end-plates showing complete or partial colocalization with neuroﬁlament staining was evaluated in the three groups (Nes-R26
Met-SOD versus SOD: P¼0.0416; controls
versus SOD: P¼0.0143; controls versus Nes-R26
Met-SOD: P¼0.0256). Values are expressed as means±S.E.M. ***Po0.001, **Po0.01, *Po0.05
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Cell Death and DiseaseALS therapy through several strategies. HGF intrathecal
administration at disease onset provided evidence that, when
present at high doses and accessible to different disease
cells, HGF/Met attenuates MN degeneration and retards
diseaseprogressionby11days.
30However,thesestudiesdid
not clarify whether, and to what extent, the HGF/Met system
exerts support on MNs in a cell-autonomous manner. Insights
to this issue come from studies based on genetic neuronal
delivery of HGF in the low copy number SOD1
G93A mice. In
particular, hgf expression driven by the neuron-speciﬁc
enolase-promoter delayed disease onset by approximately
28 days, rather than inﬂuencing its progression.
23 However,
as exogenous HGF is expressed and secreted by neurons,
these hgf transgenic mice did not allow discriminating
between the HGF effects on MNs versus those elicited on
astrocytes, which in turn inﬂuence MNs and microglia
function. Consistently, a decrease in the number of microglia,
reactive astrocytes, and MN loss was observed in hgf
transgenics. Our mouse model allowed discrimination
between the cell-autonomous effects elicited by enhanced
Met signalling in MNs and those inﬂuenced by HGF on other
dysfunctional cells. Moreover, the Nes-R26
Met mice estab-
lished that Met signalling in MNs selectively counteracts ALS
disease onset. It remains to be investigated what contribution
enhanced Met signalling, above endogenous levels in
astrocytes and microglia, could have with respect to disease
evolution.
The severity of ALS and the lack of effective therapeutic
strategies are driving efforts to explore agents, applied either
separately or in combination, to counteract disease symp-
toms. Concerning trophic factors, HGF could offer therapeutic
advantages at multiple levels. It is noteworthy that endogen-
ous Met is upregulated starting from ALS onset in ventral
spinal cords of SOD1
G93A mice (data not shown and see Sun
et al.
23). These observations indicate that endogenous Met is
turned on to counteract ALS symptoms, but endogenous
HGF levels may not be sufﬁcient to reverse the damage, as
was found studying regeneration after optic-nerve axotomy
(unpublished results). Moreover, as HGF/Met elicits functions
in muscle cells,
31,32 it is possible that ectopic HGF in muscles
would also counteract neuro-muscular-junction denervation
and muscle atrophy. Indeed, HGF favours the formation of
NMJs during development.
33 Although enhanced Met activa-
tionis often associated with tumour formation and metastasis,
we did not observe side effects such as neoplasia in
Nes-R26
Met mice despite Met
tg expression levels in regions
of the nervous system. Thus, the beneﬁcial effects of HGF/
Met on ALS degenerative processes appear to be well
tolerated in healthy nervous system tissues.
The use of the conditional ALS mouse model, in which the
mutant SOD1 gene can be deleted according to the
cre-transgenic line used, has been instrumental in clarifying
the inﬂuence of distinct cell types during ALS evolution. In
particular, selective reduction of mutant SOD1 in MNs
predominantly impacts on disease onset and its early phase.
In contrast, reduced mutant SOD1 either in astrocytes or in
microglia mainly inﬂuences the late stage of disease progres-
sion.
8,9 Thus, although recombination in Nes-R26
Met mice did
not occur in 44% of lumbar spinal cord MNs, rebalancing the
levels of stress and survival signals and/or protecting
presynaptic terminals in ALS MNs, either by providing RTK
support (our studies), or by removing signals such as BAX
inﬂuencing NMJ integrity,
12 or by depleting mutant SOD,
8,9
ameliorates ALS by selectively delaying disease onset. It is
known that the initial MN damage is followed by a progressive
increase in cytotoxic and inﬂammatory mediator levels, which
further affect MN themselves and neighbouring cells. Astro-
cytes and microglia are the predominant cell types driving
disease progression towards death. Although disease pro-
gression is unchanged in Nes-R26
Met mice, our genetic
analysis show that enhanced-neuronal Met in SOD mice
impacts on distinct cell types involved in the ALS disease:
MNs, in a cell-autonomous manner, possibly by providing
trophic support and/or maintenance of NMJ integrity and
astrocytes and microglia, in a non-cell-autonomous manner,
by delaying their activation. Future studies will establish the
relative contribution of each individual event in delaying the
onset of the disease by neuronal Met signalling and uncover
the underlying mechanisms.
Understanding how therapeutic reagents act at cellular
levels is needed to accelerate the progress of promising
treatments towards the clinic. Our ﬁndings emphasize the
relevance of genetically assessing the effects of agents on
distinct cell types implicated in a disease and during its
evolution. Although successful therapies for ALS will possibly
requireconcomitantactionsondistinctdysfunctionalcells,our
results highlight the considerable therapeutic potential of
modulating RTK signalling in MNs to combat degenerative
signals.
Materials and Methods
Generation of R26
LacZ stop Met mice. The R26
LacZ stop Met mice were
generated by taking advantage of the loxP-ﬂanked (‘ﬂoxed’)-stop cassette system.
To generate the chimeric mouse–human gene, the human Met cDNA encoding the
transmembrane and cytoplasmic portion was fused in-frame with the mouse
extracellular cDNA sequence using the PvuII site present in both sequences. We
chose such a strategy to ensure that the Met chimeric protein interacts efﬁciently
with the endogenous mouse HGF, but can still be identiﬁed from the endogenous
mouse Met protein. The fusion product was subsequently subcloned into the
pCALL2 vector downstream of the insert containing the CMV enhancer-chicken
b-actin promoter followed by the loxP-ﬂanked b-geo/3xpA cassette. This vector is
referred to as pCALL-Met. To generate the Rosa26 targeting construct, the insert
containing the CMV-enhancer/chicken-b-actin-promoter-loxP-ﬂanked b-geo/3xpA-
Met was subcloned into the XhoI site of pRosa-1 vector previously modiﬁed using a
poly-linker. The targeting vector was electroporated into R1 ES cell lines. Cell
culture, electroporation, selection, and Southern blot analyses were performed as
previously described.
32 To identify recombined clones, genomic DNA was digested
with EcoRI or EcoRV and probed with an external or internal probe, respectively.
Two selected ES cell lines carrying the homologous recombination were used to
generate the R26
LacZ stop Met mice through blastocyst injections.
Transgenic mice. The mouse line expressing cre recombinase under the
nestin promoter was previously described.
25 The B6SJL-Tg(SOD1*G93A)
1Gur(SOD1
G93A (SOD1
G93A) mouse line was used as ALS disease model.
34
Both R26
LacZ stop Met and nestin-cre mice were backcrossed into the B6SJL
geneticbackgroundbeforebreedingwiththeSOD1
G93Atransgenics.Thenumberof
mice used for behavioural and immuno-histochemical studies are indicated in ﬁgure
legends. Each genetic group consisted of a mixed population of equal numbers of
males and females. The presence of a vaginal plug in the morning was considered
as 0.5 embryonic day (E0.5). All procedures involving the use of animals were
performed in accordance with the European Community Council Directive of 24
November 1986 on the protection of animals used for experimental purposes
(86/609/EEC). The experimental protocols were carried out in compliance with
institutional ethical committee guidelines for animal research. All efforts were made
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Cell Death and Diseaseto minimize the numberof animals usedand their suffering.When paralysisstarted,
foodandwaterwereplaceddirectlyintothecage.Toreduceanimalpain,micewere
killed when they were unable to right themselves within 30s when placed on their
back.
Antibodies. Antibodies used were anti-tubulin and anti-GFAP and anti-VAChT
(1:1000; Sigma-Aldrich, St. Louis, MO, USA), anti-Met
KD (1:1000) and anti-
phospho Y1234-1235-Met (1:50; Cell Signaling, Danvers, MA, USA), anti-human
Met (1:500; Santa-Cruz Biotechnology Inc., Santa Cruz, CA, USA), anti-Smi32
(1:500; Sternberger monoclonals, Covance, Dallas, TX, USA), anti-NeuN (1:200;
Chemicon, Millipore, Billerica, MA, USA), and anti-neuroﬁlament-145 (1:1000;
AB1987; Millipore), anti-mouse or rabbit ﬂuorescent-coupled secondary antibodies
(1:400; Jackson, West Grove, PA, USA), anti-mouse or rabbit biotin-coupled
secondary antibodies (1:500; Jackson). For western blot analyses, the following
secondary antibodies were used: anti-rabbit IgG-peroxidase or anti-mouse IgG-
peroxidase (1:4000, Jackson).
Histological analysis. Anesthetizedmicewereintra-cardiacally perfusedﬁrst
with PBS then with 4% para-formaldehyde (PFA, Sigma) in PBS. Brains, spinal
cords, and muscles were dissected, postﬁxed in 4% PFA and embedded. For brain
and spinal cords, 16 or 30-mm thick cryo-sections were performed (Leica, Wetzlar,
Germany). In situ hybridization, immuno-histochemistry, and X-Gal staining were
performed as previously described.
27,35,36 MN numbers were determinedon 16-mm
thick lumbar spinal cord sections stained with VAChT antibodies or cresyl violet.
A total of 10 sections per mouse were analyzed. Astrogliosis was monitored by
measuring ﬂuorescence-levels of sections stained with anti-GFAP antibodies
(Image J software, ImageJ 1.41, NIH, Bethesda, MD, USA). For NMJ staining,
35-mm thick longitudinal sections were collected on Superfrost Plus Slides
(CML, Thermo Scientiﬁc, Braunscheweig, Germany). Tissue sections were
incubated in blocking solution (0.5% Triton X-100, 5% BSA in PBS) at 371C for
2h. Rabbit polyclonal anti neuroﬁlament-145 antibodies were diluted in the same
blocking solution and incubated overnight at 41C. Anti-rabbit-alexa 488-conjugated
secondary antibody (Invitrogen, Life Technologies, Carlsbad, CA, USA) and
a-bungarotoxin-tetramethylrhodamine-conjugate (1:1000; Invitrogen) were
incubated for 2h at room temperature (1% BSA in PBS), before washing and
mounting. Stained end-plates on sections were examined under an Axio
microscope (Zeiss, Oberkochen, Germany). Innervated (yellow) or denervated
(red) end-plates were counted on apoptome (Zeiss) 35-mm Z-stacks.
Biochemical studies. Protein extracts were prepared from freshly dissected
brains and spinal cords at the appropriate stages and western blot analyses were
performed as previously described.
37–39 Quantiﬁcations were done by measuring
band intensities with the Image J software.
Cultures. Cell culture procedures were previously described.
40 Brieﬂy, E12.5
spinal cords from R26
LacZ stop Met transgenic embryos were dissected in Hank’s
Balanced Salt Solution containing 7mM HEPES pH7.4 and 4.5g/l glucose. Cells
weredissociatedinHam-F10medium(Invitrogen)with0.025%Trypsin(Sigma)and
centrifuged over a 4% (w/v) BSA cushion at 800 g for 5min. Cells were plated on
poly-ornithine/laminin-treated coverslips in supplemented Neurobasal medium
(Invitrogen) containing neurotrophic factors (0.1ng/ml GDNF, 1ng/ml BDNF, and
10ng/mlCNTF)andmaintainedat371Cin7.5%CO2atmospherefor3daysbefore
being processed for immunochemistry. Astrocytes were prepared from P2
R26
LacZ stop Met spinal cords. When conﬂuent, cells were trypsinized and plated
onto coverslips in Dulbecco’s modiﬁed Eagle’s (DMEM, Invitrogen) medium
supplemented with 10% fetal bovine serum and penicillin–streptomycin. Cells were
then cultured at 371Ci n5 %C O 2 atmosphere for 3 days before immunostaining.
Cultured cells were processed for immunocytochemistry as above described. We
used the following primary antibodies diluted in PBS containing 4% BSA, 2%
donkeyserum:anti-b-Gal(1:4000;Cappel,MPBiomedicals,Ullkirch,France),anti-
neuroﬁlament 160 (1:600; NN18, Sigma), anti-GFAP (1:500; MAB360, Millipore).
Alexa Fluor 488 (1:500; A21206; Invitrogen) and 555 (1:1000; A31570;
Invitrogen)-conjugated donkey anti-rabbit and anti-mouse were used as
secondary antibodies (Invitrogen).
Behavioural tests. Body weight measurements and all behavioural tests
beganwhenmicereachedtheageof70daysandrecordingwasperformedweekly.
Toanalyzemotor functions,locomotortestsincluded therotarod,the1mswimming
tank and the footprint, which have been done as previously described.
27 We
performed four trials at each time point for each animal and recorded the three best
performances for statistical analysis. Brieﬂy, the rotarod test was performed by
placing mice on an accelerating rod (3cm diameter) and by recording the time each
animal took to fall from the rod. The speed of the rotarod accelerated from 4 to
40r.p.m. over a 5-min period. The swimming tank device allows evaluation of the
hindlimb strength and performance; it is suitable for assessing onset and
progression of ALS symptoms. For the swimming tank, each mouse performed four
trials and the time needed to reach the platform was recorded. A mouse was
considered at the onset of motor defect when it needed 6.8s to perform the
swimming tank test. The 6.8s were chosen as reference as this value corresponds
to the ﬁrst signiﬁcant difference versus control mice. For the footprint test, the fore-
toes and the hind-toes were labelled in blue and red, respectively. Weekly
monitoring of walking patterns allows assessment of motor coordination and
synchrony through the evaluation of several parameters, including toe spread,
forepaw/hindpawoverlap,andstep-length.Twoparametersweremeasured:(1)the
overlap distance between forepaw and hindpaw on the same side; (2) the stride
length as the distance of the hindpaw on the same side between each step. For the
overlap, the Kaplan–Meier curve indicates the mice when the distance between
forepaw and hindpaw increased by 45%. For the step length, the Kaplan–Meier
curve indicates when the distance of the hindpaw for each step decreased by 40%.
To reduce mouse stress and fatigue, the swimming and the footprint behavioural
tests were carried out on different days.
Statistical analysis. Results were expressed as the mean±S.E.M.
Statistically signiﬁcant differences on cell counts were assessed by the Student’s
t-test. Statistically signiﬁcant differences among the groups of mice were assessed
by two-way ANOVA. Post hoc Bonferroni’s correction was also used to test all pair-
wise comparisons between groups and time points per group. A log-rank test was
used to calculate the statistical differences in the onset and survival of the different
mouse cohorts. Statistical signiﬁcance was deﬁned as ns: P40.05; *Po0.05;
**Po0.01; ***Po0.001.
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